Uthever®︎ Clinical Study


UTHEVER Preclinical Study

Effepharm has conducted some preclinical studies on Uthever® to prove the safety of NMN, which include:

Five animal and cell studies:

(1) Acute toxicity study
(2) 90-day subchronic oral study
(3) Bacterial mutagenesis-Ames
(4) In vitro cytogenetics-Chromosome aberration test in CHO cell lines
(5) In vivo mammalian test-Chromosome aberration test in Mouse

Results will be published soon. 

More animal studies on efficacy have been conducted as well.

(1) NMN Combined With Lactobacillus fermentum TKSN041 Reduces the Photoaging Damage

(2) β-Nicotinamide Mononucleotide (NMN) Administrated by Intraperitoneal Injection Mediates Protection Against UVB-Induced Skin Damage in Mice

(3) Effect of NMN on DSS-induced ulcerative colitis in mice

(4) Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models

Understanding the Endogenous Molecule: NMN

The advancement of Medical Sciences has led to an increase in human lifespan, resulting in a growing interest in exploring anti-ageing compounds. This has brought about an increased interest in endogenous compounds, which are thought to have some potential to help individuals achieve healthy and productive lives even in old age.

NMN is one such endogenous molecule and is involved in nicotinamide adenine dinucleotide (NAD+) biosynthesis, a critical cofactor in cellular processes. Involved in fundamental biological processes, NAD+ depletion is associated with ageing and age-related diseases. This is where supplementation through NMN comes into the picture.

Motivating Factors Behind Conducting NMN Clinical Trials

NMN supplementation has shown potential in preclinical trials for conditions linked to NAD+ deficiency. As a matter of fact, NMN can compensate for NAD+ depletion caused by NAD+ consuming enzymes. Moreover, NMN has fewer adverse side effects compared to other NAD+ precursors.

Preclinical studies have also demonstrated NMN’s pharmacological activities in various health conditions like Cardiac and Cerebral Ischemia, Alzheimer’s disease, diet-and age-induced Type 2 Diabetes, and Obesity — all of which are related to NAD+ deficiency. These promising results in human interventions have further supported the safety of NMN supplementation.

However, limited data exist on its efficacy as an anti-ageing supplement. This study thus aimed to investigate the safety and efficacy of Uthever® NMN, the first branded NMN ingredient. It is a type of NMN supplementation designed to simulate NAD+ metabolism and assess its anti-ageing effects in middle-aged and older adults.

This independent investigation represents EffePharm’s unwavering commitment to offering safe and potent NMN products. These comprehensive clinical trials have also allowed us to gather valuable data and insights into the side effects of NMN on human health, propelling us to the forefront of NMN research and development.

NMN Clinical Study Overview

Our study, titled “A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever® (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults”, was structured as a multi-centre, randomised, double-blind, parallel design, placebo-controlled trial.

The Clinical Trial Design

A well-constructed clinical trial is essential for obtaining reliable and valid data.

The Uthever® trial’s design was dissected as follows to highlight the meticulous structure of this independent clinical trial:

(1) Multi-centre: This denotes that the trial was conducted in multiple locations, a strategy that helps to accumulate a diverse participant base, thereby improving the generalisability of the findings.
(2) Randomised: This process involves randomly assigning participants to either the NMN or placebo group, an approach that minimises biases and ensures any observed effects can be attributed to NMN. Registered in the US under the ID NCT04228640 NMN, our interventional clinical trial aimed to recruit 66 healthy participants between the ages of 40 and 65 years old for a randomised allocation process.
(3) Double-Blind: In a double-blind study, neither the participants nor the investigators know who is receiving NMN or the placebo. This setup further eliminates bias, providing more reliable results.
(4) Parallel Design: This implies that the NMN and placebo groups were studied simultaneously, enhancing the study’s efficiency and allowing for a direct comparison of outcomes. And our intervention model consisted of a parallel assignment to ensure even distribution across the different trial groups.
(5) Placebo-Controlled: This means a group was given a placebo (an inactive substance) to compare the side effects of NMN against the natural course of ageing.

Interpreting Biomarkers in the NMN Clinical Trial

The Uthever® clinical trial employed an array of biomarkers to evaluate NMN’s effectiveness with the primary goal of prevention in mind. Among them, blood cellular NAD+/NADH concentration in serum, physical tests, Body Mass Index (BMI) evaluations, and Homeostatic Model Assessment (HOMA) scoring were also central in assessing NMN’s safety and potential side effects.

The Tripartite Focus of the Uthever® Clinical Trial

Our clinical trial was meticulously designed to scrutinise three primary components of NMN:

(1) A comprehensive safety assessment of NMN
(2) Investigating NMN’s function in anti-ageing
(3) Evaluating NMN’s capacity for energy augmentation and endurance enhancement

These elements were chosen as they form the crux of NMN’s potential benefits, thereby allowing us to evaluate Uthever®’s performance in these critical areas.

The Uthever® Promise: A New Era of Health and Longevity

At EffePharm, we’re not just a private label NMN manufacturer; we aim to carve a path in a new era of health and longevity. Our commitment to quality and safety is evident in the comprehensive clinical trials performed by EffePharm, leading to a range of NMN products that can make a difference in people’s lives.

Elevate your health with Uthever®. Browse our collection of NMN products and make your purchase from our range of wholesale NMN products. Embark on your journey towards a healthier, revitalised life with EffePharm today!

Commitment to Transparency: Registering the Uthever® Clinical Study

We stand by the principle of transparency. Thus, the Uthever® clinical study was registered in both the US and the World Health Organisation’s (WHO) official clinical registry systems. All our study details, procedures, and findings are made public, fostering an open dialogue about our work and its implications for the future of NMN.

Learn more about our study:

doi: 10.3389/fragi.2022.851698
Download full article